Prostate cancer remains one of the most common cancers among men in the United States, and early detection is crucial for effective treatment. The 2025 guidelines for prostate cancer screening emphasize shared decision-making between patients and healthcare providers, especially for men ages 55 to 69. New recommendations highlight the importance of individualized screening plans, considering risk factors such as family history, African American ancestry, and genetic mutations. Advances in prostate cancer screening now include PSA testing, MRI-based diagnostics, and genetic biomarker analysis, all designed to improve accuracy and reduce unnecessary procedures. Men at higher risk may benefit from earlier or more frequent screening, while the potential risks of overdiagnosis and overtreatment remain important considerations. Talk to your doctor about the latest screening options and how they may impact your prostate health.